Regorafenib versus Cetuximab plus Irinotecan in Third-line Metastatic Colorectal Cancer in Iran: A Model-based Cost-utility Analysis
Background: Metastatic colorectal cancer (mCRC) constitutes a significant health burden globally, accompanied by elevated mortality rates. This study aimed to assess the cost-effectiveness of regorafenib, an orally administered multi-kinase inhibitor, compared to the combination of Cetuximab and Iri...
| Հիմնական հեղինակներ: | , , , |
|---|---|
| Ձևաչափ: | Հոդված |
| Լեզու: | English |
| Հրապարակվել է: |
Shiraz University of Medical Sciences
2024-10-01
|
| Շարք: | Middle East Journal of Cancer |
| Խորագրեր: | |
| Առցանց հասանելիություն: | https://mejc.sums.ac.ir/article_49973_a7eb6e2982704e407ace6f7479b4be59.pdf |